Log in

NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, Forecast & News

$0.90
-0.06 (-6.27 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$0.89
Now: $0.90
$1.01
50-Day Range
$0.76
MA: $0.90
$1.29
52-Week Range
$0.72
Now: $0.90
$4.14
Volume942,662 shs
Average Volume650,023 shs
Market Capitalization$44.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.5
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLCM
CUSIPN/A
Phone832-384-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book Value$1.58 per share

Profitability

Net Income$-98,040,000.00
Net Margins-4,768.13%

Miscellaneous

Employees173
Market Cap$44.80 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive BLCM News and Ratings via Email

Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter.


Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) released its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.04. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analysts' expectations of $0.23 million. Bellicum Pharmaceuticals had a negative net margin of 4,768.13% and a negative return on equity of 280.67%. View Bellicum Pharmaceuticals' Earnings History.

When is Bellicum Pharmaceuticals' next earnings date?

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Bellicum Pharmaceuticals.

Has Bellicum Pharmaceuticals been receiving favorable news coverage?

News stories about BLCM stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Bellicum Pharmaceuticals.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,860,000 shares, an increase of 17.7% from the October 31st total of 1,580,000 shares. Based on an average daily volume of 860,500 shares, the days-to-cover ratio is currently 2.2 days. Approximately 4.1% of the company's shares are sold short. View Bellicum Pharmaceuticals' Current Options Chain.

Who are some of Bellicum Pharmaceuticals' key competitors?

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), Cyberark Software (CYBR), AVEO Pharmaceuticals (AVEO), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), FireEye (FEYE), NVIDIA (NVDA) and Editas Medicine (EDIT).

Who are Bellicum Pharmaceuticals' key executives?

Bellicum Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
  • Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
  • Mr. Thomas J. Farrell, Consultant (Age 56)
  • Mr. Atabak Mokari, Chief Financial Officer (Age 42)
  • Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray served as the underwriters for the IPO and Trout Capital was co-manager.

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.09%), Nikko Asset Management Americas Inc. (5.09%), Millennium Management LLC (0.09%), Sabby Management LLC (0.08%) and Squarepoint Ops LLC (0.08%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Alan K Smith, Bros Advisors Lp Baker, David M Spencer, Jon P Stonehouse, Richard A Fair and Shane Ward. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Which major investors are selling Bellicum Pharmaceuticals stock?

BLCM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Which major investors are buying Bellicum Pharmaceuticals stock?

BLCM stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and Sabby Management LLC. Company insiders that have bought Bellicum Pharmaceuticals stock in the last two years include Jon P Stonehouse, Richard A Fair and Shane Ward. View Insider Buying and Selling for Bellicum Pharmaceuticals.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $0.90.

How big of a company is Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals has a market capitalization of $44.80 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals.

What is Bellicum Pharmaceuticals' official website?

The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]


MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel